Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
9 hedge funds and large institutions have $1.15M invested in Immune Pharmaceuticals Inc. in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$890K |
| 2 |
EEG
E.E. Geduld
|
+$142K |
| 3 |
Goldman Sachs
New York
|
+$111K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$80K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71.2K |
Top Sellers
IMNP Hedge Fund Activity: Q3 2014 in Review
9 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q3 2014, worth a combined $1.15M.
Buyers outnumbered sellers: 9 funds opened new IMNP positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Pine River Capital Management, opening a new position worth an estimated $890K.
- 9 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $1.15M of Immune Pharmaceuticals Inc. stock for Q3 2014.
- 9 funds opened new Immune Pharmaceuticals Inc. positions in Q3 2014 and 0 closed out, a net change of +9 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q3 2014 was Pine River Capital Management, an estimated $890K added.
Based on aggregated 13F filings for Q3 2014.